澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sunitinib malate, quantity: 50.119 mg (equivalent: sunitinib, qty mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - arx-sunitinib is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 25 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 20 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified water; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 7.5 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 2.5 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 5 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 10 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine is indicated for the treatment of patients with: ? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

key pharmaceuticals ltd - nortriptyline hydrochloride - oral tablet - 10mg